EA no 3798 Détection et Approches Thérapeutiques Nanotechnologiques dans Mécanismes Biologiques de Défense, Université de Reims Champagne-Ardenne, Reims, France.
Proteomics. 2010 Feb;10(4):700-16. doi: 10.1002/pmic.200900540.
The occurrence of metastases is one of the main causes of death in many cancers and the main cause of death for breast cancer patients. Micrometastases of disseminated tumour cells and circulating tumour cells are present in more than 30% of breast cancer patients without any clinical or even histopathological signs of metastasis. Low abundance of these cell types in clinical diagnostic material dictates the necessity of their enrichment prior to reliable detection. Current micrometastases detection techniques are based on immunocytochemical and molecular methods suffering from low efficiency of tumour cells enrichment and observer-dependent interpretation. The use of highly fluorescent semiconductor nanocrystals, also known as "quantum dots" and nanocrystal-encoded microbeads tagged with a wide panel of antibodies against specific tumour markers offers unique possibilities for ultra-sensitive micrometastases detection in patients' serum and tissues. The nanoparticle-based diagnostics provides an opportunity for highly sensitive parallel quantification of specific proteins in a rapid and low-cost method, thereby providing a link between the primary tumour and the micrometastases for early diagnosis.
转移的发生是许多癌症患者死亡的主要原因之一,也是乳腺癌患者死亡的主要原因。在没有任何临床甚至组织病理学转移迹象的情况下,超过 30%的乳腺癌患者存在播散性肿瘤细胞和循环肿瘤细胞的微转移。这些细胞类型在临床诊断材料中的低丰度决定了在可靠检测之前必须对其进行富集。目前的微转移检测技术基于免疫细胞化学和分子方法,存在肿瘤细胞富集效率低和观察者依赖性解释的问题。高度荧光半导体纳米晶体(也称为“量子点”)和用针对特定肿瘤标志物的广泛抗体标记的纳米晶编码微珠的使用为在患者的血清和组织中进行超灵敏微转移检测提供了独特的可能性。基于纳米颗粒的诊断为在快速和低成本的方法中高度敏感地平行定量特定蛋白质提供了机会,从而在早期诊断中为原发性肿瘤和微转移之间建立了联系。